Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine. — CFSMEATLAS
Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine.
Joseph, Phillip, Pari, Rosa, Miller, Sarah et al. · Chest · 2022 · DOI
Quick Summary
This study tested whether a medication called pyridostigmine could help people with ME/CFS exercise better by improving blood flow and heart function. Researchers gave 45 ME/CFS patients either pyridostigmine or a placebo, then measured their exercise capacity twice using specialized heart and lung tests. The group taking pyridostigmine showed improved oxygen uptake and better heart function during exercise, while the placebo group actually got worse, suggesting the medication may help counteract some of the body's dysfunctional responses to exercise in ME/CFS.
Why It Matters
This study provides mechanistic evidence that neurovascular dysregulation—a treatable condition—may underlie exercise intolerance in ME/CFS, offering hope for a potential targeted therapeutic approach. If confirmed in larger trials, pyridostigmine or similar agents could provide symptom relief for patients with postexertional malaise and orthostatic intolerance, two hallmark and disabling features of ME/CFS.
Observed Findings
Peak VO₂ increased after pyridostigmine (+13.3 mL/min) but decreased after placebo (-40.2 mL/min), a difference of 53.6 mL/min (P<0.05).
Cardiac output improved more in the pyridostigmine group (-0.2 L/min) compared to placebo (-1.9 L/min, P<0.05).
Right atrial pressure increased after pyridostigmine (+1.0 mm Hg) but decreased after placebo (-0.6 mm Hg, P<0.05).
The placebo group showed worsening hemodynamics between exercise tests, potentially reflecting postexertional malaise.
Inferred Conclusions
Neurovascular dysregulation, characterized by impaired cardiac output and ventricular filling, contributes to acute exercise intolerance in ME/CFS.
Cholinergic stimulation via pyridostigmine can acutely improve exercise capacity by enhancing cardiac output and right ventricular filling pressures.
Postexertional malaise may be mechanistically linked to deterioration in hemodynamic function after exertion.
Neurovascular dysregulation in ME/CFS represents a potentially treatable underlying cause rather than an inevitable consequence of the disease.
Remaining Questions
Does pyridostigmine improve exercise capacity with repeated or chronic dosing, and do benefits persist over weeks or months?
What This Study Does Not Prove
This study does not prove that pyridostigmine is an effective long-term treatment for ME/CFS—it only shows acute effects in a single exercise session. It does not establish that neurovascular dysregulation is the sole cause of ME/CFS, only that it may contribute to acute exercise intolerance. The study cannot determine whether these improvements would persist with repeated dosing or benefit all ME/CFS patients, as responders and non-responders were not distinguished.